



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

The new Pharmacovigilance legislation and implementation planning

Second Stakeholders meeting 17 June 2011

European Medicines Agency, London, UK

Presented by: Franck Diafouka
Project Manager, Pharmacovigilance and Risk Management sector

An agency of the European Union





Agenda

1. Implementing the new legislation: Governance

- EMA;
- EU Network;
- Working methodology;
- Reporting timelines;
- Stakeholders liaison.

2. Implementing the new legislation: Deliverables

- Implementation phasing plan;
- EMA/Member States technical contribution to EC draft Implementing Measures and Concept Papers;




Governance – EMA (1/5)

- EMA Project 00305: Cross-Agency Task Force
 - Established Jan 2010
 - Monthly meetings
- Initial mandate:
 - Assess in detail the impact of the new legislative proposal on the European Medicines Agency activities or operations
 - Deliver on time the measures necessary to implement the new legislation




1. Governance – EU Network (2/5)






1. Governance – working methodology (3/5)





1. Governance – Reporting timelines (4/5)





1. Governance - Stakeholders liaison and consultation (5/5)

- Stakeholders meetings involving EMA, Member States, EC, Industry, Patients and Healthcare Professionals representatives:
 - 15th April 2011 (positive feedback)
 - 17th June 2011
 - More later in the year.....
- Formal public consultations by EC and EMA



2. What will be delivered?(1/6)

Hierarchy of rules

Deliverables

- **Regulation** (EC) 1235/2010
- **Directive** 2010/84/EC

EC Implementing Measures

= Commission regulation

(Reg. Art. 87a and Dir. Art. 108)

- **Policies**
- **Operations**
- **ICT**

Concept Papers

Process Mapping

IT requirements

EMA/MSs
Technical contribution

Guidelines


SOP/WIN/Templates

IT tools



2. What will be delivered? (2/6)

Implementation phasing plan





2. What will be delivered? (3/6)

EMA/Member States technical contribution to EC implementing measures

Reg. (EC) 1235/2010 Art. 87a and Dir. 2010/84/EC Art. 108

- (a) The content and maintenance of the pharmacovigilance system master file kept by the MAH;
- (b) The minimum requirements for the quality system for the performance of pharmacovigilance activities by the **Agency, the NCAs and MAH**;
- (c) The use of internationally agreed terminology, formats and standards for the performance of pharmacovigilance activities;



2. What will be delivered? (4/6)

EMA/Member States technical contribution to EC implementing measures

Reg. (EC) 1235/2010 Art. 87a and Dir. 2010/84/EC Art. 108

- (d) The minimum requirements for the monitoring of data included in the EV database to determine whether there are new risks or whether risks have changed;
- (e) The format and content of electronic transmission of suspected adverse reactions by MSs and MAHs;
- (f) The format and content of electronic PSURs and RMPs;
- (g) The format of protocols, abstracts and final study reports of the PASS;



2. What will be delivered? (5/6)

Several Concept Papers under preparation


- Pharmacovigilance audits
- Coordination of safety announcements
- EU medicines Web-portal
- Products under additional monitoring
- Public hearings
- Transparency
- Etc,....




2. What will be delivered? (6/6)

Structure of implementing measures and Good Vigilance Practice: 'GVP'

EC Implementing measures



Good Vigilance Practice guidelines





Any questions?



List of abbreviations

ERMS-FG: European Risk Management Strategy – Facilitation Group

PSUR: Periodic Safety Update Report

ADR: Adverse Drug Reaction

RMP/S: Risk Management Plan/System

EV: EudraVigilance

PAE/SS: Post-Authorisation Efficacy/Safety Studies

SOP: Standard Operating Procedure

WIN: Working Instruction

ICT: Information and Communication Technology

EMA: European Medicines Agency

MSs: Member States